PANTOPRAZOLE SODIUM- pantoprazole sodium tablet, delayed release

Negara: Amerika Serikat

Bahasa: Inggris

Sumber: NLM (National Library of Medicine)

Bahan aktif:

PANTOPRAZOLE SODIUM (UNII: 6871619Q5X) (PANTOPRAZOLE - UNII:D8TST4O562)

Tersedia dari:

Jubilant Cadista Pharmaceuticals Inc.

INN (Nama Internasional):

PANTOPRAZOLE SODIUM

Komposisi:

PANTOPRAZOLE 20 mg

Rute administrasi :

ORAL

Jenis Resep:

PRESCRIPTION DRUG

Indikasi Terapi:

Pantoprazole sodium delayed-release tablets are indicated for: Pantoprazole sodium delayed-release tablets are indicated in adults and pediatric patients five years of age and older for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis (EE). For those adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium delayed-release tablets may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. Pantoprazole sodium delayed-release tablets are indicated for maintenance of healing of EE and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. Pantoprazole sodium delayed-release tablets  are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison (ZE) Syndrome. - Pantoprazole sodium is contraindicated in patients with kn

Ringkasan produk:

How Supplied Pantoprazole Sodium Delayed-Release Tablets USP 20 mg (pantoprazole) are light pink to pink colored, biconvex, circular, coated tablets, imprinted with ‘C283’ on one side and plain on the other side.  Bottles of 30 (child-resistant closure)                  NDC 59746-283-30 Bottles of 90 (child-resistant closure)                  NDC 59746-283-90 Bottles of 100 (child-resistant closure)                NDC 59746-283-01 Bottles of 500                                                      NDC 59746-283-05 Bottles of 1000                                                    NDC 59746-283-10 10 x 10 Unit-dose Tablets                                   NDC 59746-283-03 Pantoprazole Sodium Delayed-Release Tablets USP 40 mg (pantoprazole ) are light pink to pink colored, biconvex, oval, coated tablets, imprinted with ‘C284’ on one side and plain on the other side. Bottles of 30 (child-resistant closure)                  NDC 59746-284-30 Bottles of 90 (child-resistant closure)                  NDC 59746-284-90 Bottles of 100 (child-resistant closure)                 NDC 59746-284-01 Bottles of 500                                                      NDC 59746-284-05 Bottles of 1000                                                    NDC 59746-284-10 10 x 10 Unit-dose Tablets                                   NDC 59746-284-03 Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

Status otorisasi:

Abbreviated New Drug Application

Selebaran informasi

PANTOPRAZOLE SODIUM - pantoprazole sodium tablet, delayed release
Jubilant Cadista Pharmaceuticals Inc.
----------
MEDICATION GUIDE
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS USP
(pan toe’ pra zole soe’ dee um)
What is the most important information I should know about
pantoprazole sodium delayed-release tablets?
You should take pantoprazole sodium delayed-release tablets exactly as
prescribed, at the lowest dose
possible and for the shortest time needed.
Pantoprazole sodium delayed-release tablets may help your acid-related
symptoms, but you could still have
serious stomach problems. Talk with your doctor.
Pantoprazole sodium delayed-release tablets can cause serious side
effects, including:
•
A type of kidney problem (acute interstitial nephritis). Some people
who take proton pump inhibitor
(PPI) medicines, including pantoprazole sodium delayed-release
tablets, may develop a kidney
problem called acute interstitial nephritis that can happen at any
time during treatment with
pantoprazole sodium delayed-release tablets. Call your doctor right
away if you have a decrease in the
amount that you urinate or if you have blood in your urine.
•
Diarrhea caused by an infection (Clostridium difficile) in your
intestines. Call your doctor right away
if you have watery stools or stomach pain that does not go away. You
may or may not have a fever.
•
Bone fractures (hip, wrist, or spine). Bone fractures in the hip,
wrist, or spine may happen in people
who take multiple daily doses of PPI medicines and for a long period
of time (a year or longer). Tell
your doctor if you have a bone fracture, especially in the hip, wrist,
or spine.
•
Certain types of lupus erythematosus. Lupus erythematosus is an
autoimmune disorder (the body’s
immune cells attack other cells or organs in the body). Some people
who take PPI medicines,
including pantoprazole sodium delayed-release tablets, may develop
certain types of lupus
erythematosus or have worsening of the lupus they already have. Call
your doctor right away if you
have new

Karakteristik produk

PANTOPRAZOLE SODIUM - PANTOPRAZOLE SODIUM TABLET, DELAYED RELEASE
JUBILANT CADISTA PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
PANTOPRAZOLE SODIUM
DELAYED-RELEASE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS.
PANTOPRAZOLE SODIUM DELAYED-RELEASE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 2000
RECENT MAJOR CHANGES
Warnings and Precautions, Fundic Gland Polyps (5.9) 06/2018
INDICATIONS AND USAGE
Pantoprazole sodium delayed-release tablets are proton pump inhibitor
(PPI) indicated for the following:
Short-Term Treatment of Erosive Esophagitis Associated with
Gastroesophageal Reflux Disease (GERD)
(1.1)
Maintenance of Healing of Erosive Esophagitis (1.2)
Pathological Hypersecretory Conditions Including Zollinger-Ellison
(ZE) Syndrome (1.3)
DOSAGE AND ADMINISTRATION
INDICATION
DOSE
FREQUENCY
SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD (2.1)
Adults
40 mg
Once Daily for up to 8 wks
Children (5 years and older)
≥ 15 kg to < 40 kg
≥ 40 kg
20 mg
40 mg
Once Daily for up to 8 wks
MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS (2.1)
Adults
40 mg
Once Daily*
PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON
SYNDROME (2.1)
Adults
40 mg
Twice Daily
* Controlled studies did not extend beyond 12 months
See full prescribing information for administration instructions
DOSAGE FORMS AND STRENGTHS
Delayed-Release Tablets: 20 mg and 40 mg pantoprazole (3)
CONTRAINDICATIONS
Patients with known hypersensitivity to any component of the
formulation or to substituted
benzimidazoles (4)
Patients receiving rilpivirine-containing products (4,7)
WARNINGS AND PRECAUTIONS
Gastric Malignancy: In adults, symptomatic response does not preclude
presence of gastric
malignancy. Consider additional follow-up and diagnostic testing.
(5.1)
Acute Interstitial Nephritis: Observed in patients taking PPIs. (5.2)
_Clostridium difficile-_Associated Diarrhea: PPI t